Data support potential clinical use as a cancer immunotherapy treatment in various combinations with COM701 and PD-1 inhibitors
HOLON, Israel I November 5, 2019 ICompugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902 anti-TIGIT program supporting its potential clinical use in various combinations with PD-1 inhibitors and COM701, a first-in-class PVRIG inhibitor. The findings will be presented in a poster titled “COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo” at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) in National Harbor, Maryland, on Saturday, November 9, 2019.
“These new preclinical data further substantiate our theory that TIGIT and PVRIG are part of a foundational immuno-oncology axis, the DNAM axis,” said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “We believe that a combined treatment of COM902 with COM701, our first-in-class PVRIG antibody, has the potential to enhance the clinical impact of cancer immunotherapy in patients unresponsive to approved treatments. We look forward to advancing COM902 to the clinic early next year.”
Key findings in the poster include:
- Broad expression of TIGIT and PVRIG ligands, PVR and PVRL2 in solid tumors.
- Superior binding affinity of COM902 to T cells with similar and or greater in vitro function compared to several clinical anti-TIGIT antibodies.
- Increased T cell activation by COM902 on tumor infiltrating lymphocytes (TILs), which was further enhanced by combination with COM701.
- Reduced mouse melanoma tumor growth in TIGIT and PVRIG knockout mice with further tumor growth reduction in TIGIT/PVRIG double knockouts.
- COM902 inhibited tumor growth and increased survival when combined with anti-PVRIG or anti-PD-L1 antibodies in a mouse model of colon cancer.
The poster will be available on Compugen’s website following the poster presentation.
About COM902
COM902, a high affinity, fully human antibody targeting TIGIT, was developed for combination treatment with COM701. Preclinical data demonstrate that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T cell activation and increase anti-tumor immune responses. Parallel inhibition of TIGIT and PVRIG, the two coinhibitory arms of the DNAM-1 axis, results in synergistic effects on effector T cell function and tumor growth inhibition in various model systems that can be further increased with the addition of PD-1 blockade. Based on preclinical data these combinations may be clinically important for enhancing anti-tumor immune response and expanding the patient population responsive to checkpoint inhibition. The Company plans to initiate Phase 1 studies in patients with advanced malignancies in early 2020 pursuant to the FDA’s clearance of an investigational new drug application in October 2019.
Compugen discovered TIGIT in 2009 leveraging its immune checkpoint computational discovery platform through which PVRIG was also discovered. The TIGT discovery was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered computationally, including T cell immune checkpoints and additional early-stage immune-oncology programs focused largely on myeloid targets. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with facilities in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen’s corporate website at www.cgen.com.
SOURCE: Compugen
Post Views: 27
Data support potential clinical use as a cancer immunotherapy treatment in various combinations with COM701 and PD-1 inhibitors
HOLON, Israel I November 5, 2019 ICompugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preclinical results from its COM902 anti-TIGIT program supporting its potential clinical use in various combinations with PD-1 inhibitors and COM701, a first-in-class PVRIG inhibitor. The findings will be presented in a poster titled “COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo” at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) in National Harbor, Maryland, on Saturday, November 9, 2019.
“These new preclinical data further substantiate our theory that TIGIT and PVRIG are part of a foundational immuno-oncology axis, the DNAM axis,” said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “We believe that a combined treatment of COM902 with COM701, our first-in-class PVRIG antibody, has the potential to enhance the clinical impact of cancer immunotherapy in patients unresponsive to approved treatments. We look forward to advancing COM902 to the clinic early next year.”
Key findings in the poster include:
- Broad expression of TIGIT and PVRIG ligands, PVR and PVRL2 in solid tumors.
- Superior binding affinity of COM902 to T cells with similar and or greater in vitro function compared to several clinical anti-TIGIT antibodies.
- Increased T cell activation by COM902 on tumor infiltrating lymphocytes (TILs), which was further enhanced by combination with COM701.
- Reduced mouse melanoma tumor growth in TIGIT and PVRIG knockout mice with further tumor growth reduction in TIGIT/PVRIG double knockouts.
- COM902 inhibited tumor growth and increased survival when combined with anti-PVRIG or anti-PD-L1 antibodies in a mouse model of colon cancer.
The poster will be available on Compugen’s website following the poster presentation.
About COM902
COM902, a high affinity, fully human antibody targeting TIGIT, was developed for combination treatment with COM701. Preclinical data demonstrate that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T cell activation and increase anti-tumor immune responses. Parallel inhibition of TIGIT and PVRIG, the two coinhibitory arms of the DNAM-1 axis, results in synergistic effects on effector T cell function and tumor growth inhibition in various model systems that can be further increased with the addition of PD-1 blockade. Based on preclinical data these combinations may be clinically important for enhancing anti-tumor immune response and expanding the patient population responsive to checkpoint inhibition. The Company plans to initiate Phase 1 studies in patients with advanced malignancies in early 2020 pursuant to the FDA’s clearance of an investigational new drug application in October 2019.
Compugen discovered TIGIT in 2009 leveraging its immune checkpoint computational discovery platform through which PVRIG was also discovered. The TIGT discovery was published by Compugen in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered computationally, including T cell immune checkpoints and additional early-stage immune-oncology programs focused largely on myeloid targets. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with facilities in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen’s corporate website at www.cgen.com.
SOURCE: Compugen
Post Views: 27
